Clinical Trial Update: Shift to Everolimus (RAD) Kidney Sparing Study [Phase 4]

View source ↗

Summary

A Phase 4 kidney-sparing study evaluating Everolimus (RAD) for patients with kidney dysfunction in the context of heart transplantation has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Transplantation
• Kidney Dysfunction

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: University of Bologna | Conditions: Kidney Dysfunction, Heart Transplantation | Phase 4 | Status: TERMINATED